Jain Arihant, Singh Charanpreet, Dhawan Rishi, Jindal Nishant, Mohindra Ritin, Lad Deepesh, Prakash Gaurav, Khadwal Alka, Suri Vikas, Bhalla Ashish, Kumari Savita, Varma Neelam, John M Joseph, Mahapatra Manoranjan, Malhotra Pankaj
Department of Internal Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012 India.
Department of Hematology, All India Institute of Medical Education and Research, New Delhi, India.
Indian J Hematol Blood Transfus. 2020 Oct;36(4):605-615. doi: 10.1007/s12288-020-01300-0. Epub 2020 Jun 6.
The current pandemic coronavirus, SARS-CoV-2, is known to cause severe infection (COVID-19) in patients with comorbidities, particularly cancer or an immunosuppressed state. Most healthcare systems in the country are likely to be overwhelmed soon if the pandemic moves to a stage of community transmission. Currently, limited evidence is available for managing patients with hematological disorders during the COVID-19 pandemic. The current review summarises the possible challenges clinicians are likely to face, key considerations to guide decision making, and possible solutions to the anticipated challenges. Disease specific recommendations and possible guidance for decision making have been suggested for most hematologic diseases that are feasible in our health setup. It is not meant to replace individual clinical judgment, but to provide a template to formulate local policies.
目前已知大流行的冠状病毒SARS-CoV-2会在患有合并症的患者中引起严重感染(COVID-19),尤其是癌症患者或免疫抑制状态患者。如果疫情进入社区传播阶段,该国大多数医疗系统可能很快不堪重负。目前,关于在COVID-19大流行期间管理血液系统疾病患者的证据有限。本综述总结了临床医生可能面临的潜在挑战、指导决策的关键考虑因素以及应对预期挑战的可能解决方案。针对我们医疗环境中可行的大多数血液系统疾病,提出了针对特定疾病的建议和可能的决策指导。它并非旨在取代个人临床判断,而是提供一个制定地方政策的模板。